• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Simponi (golimumab) - Articles and news items

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

SMC accepts five new medicines; rejects eculizumab

Industry news / 9 February 2016 / Victoria White

The committee was unable to accept eculizumab as it was “not considered to represent an effective use of NHS Scotland’s resources”…

EC approves Simponi for the treatment of severe, active non-radiographic axial spondyloarthritis

Industry news / 26 June 2015 / Victoria White

The EC has approved Simponi (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA)…

Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR

Industry news / 11 June 2015 / Victoria White

Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR…

CHMP adopts positive opinion of Simponi for the treatment of non-radiographic axial spondyloarthritis

Industry news / 26 May 2015 / Victoria White

CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis…

MSD Logo

New data at ACR meeting show efficacy of Simponi® (golimumab) in treating patients with active non-radiographic axial spondyloarthritis

Industry news / 19 November 2014 / MSD

Application for approval of new indication for golimumab has been filed with the European Medicines Agency…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +